Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Vergent Bioscience

Vergent Bioscience to Present Data on Abenacianine for Injection (VGT-309) at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
From Vergent Bioscience
Via Business Wire
Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries
From Vergent Bioscience
Via Business Wire
Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries
From Vergent Bioscience
Via Business Wire
Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer
From Vergent Bioscience
Via Business Wire
Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309
From Vergent Bioscience
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.